Form 4: United Therapeutics CEO Vests RSUs, Adjusts Holdings
Insider Transaction Report
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp, reported the vesting of restricted stock units and subsequent share adjustments for tax purposes.
Summary
- Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (UTHR), reported transactions on March 15, 2026.
- Acquired a total of 69,579 shares of common stock (32,499 and 37,080 shares) through the vesting of performance-based restricted stock units (RSUs).
- Disposed of 29,196 shares of common stock (13,637 and 15,559 shares) at a price of $536.12 per share to cover tax obligations related to the RSU vesting.
- Following these transactions, direct beneficial ownership stands at 40,513 shares of common stock.
- Indirect beneficial ownership includes 166 shares by spouse and 639,193 shares held across various family trusts.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this filing as moderately positive for the insider, as it reflects the realization of compensation through RSU vesting. For the company, it is largely neutral as it represents a pre-scheduled compensation event rather than a discretionary open market transaction.
Positives
- The vesting of 69,579 restricted stock units represents a significant increase in the CEO's direct equity stake in United Therapeutics Corp, demonstrating continued alignment with shareholder interests.
- The transactions reflect the successful achievement of performance metrics tied to the restricted stock units.
Negatives
- A total of 29,196 shares were disposed of to cover tax liabilities, which slightly reduces the net increase in direct ownership from the RSU vesting.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
StockSavvy.ai notes that routine insider filings like Form 4, which report pre-scheduled RSU vesting and tax-related dispositions, are common across the biotechnology and pharmaceutical sectors. These transactions typically reflect previously established compensation plans rather than new strategic moves or changes in management's outlook on the company's prospects.
Related Party Transactions
- Shares are held indirectly in various family trusts (Trusts 3, 4, 5, and 6) where the Reporting Person, their spouse, and/or immediate family members are beneficiaries or have investment/revocation powers.
Stakeholder Impact
- Shareholders: The increase in the CEO's direct ownership through RSU vesting aligns management's interests with those of shareholders, potentially signaling confidence in the company's long-term value.
- Employees: The RSU vesting demonstrates the execution of performance-based compensation, which can serve as a positive example for other employees under similar incentive plans.
Key Dates
| Date | Description |
|---|---|
| 03/15/2026 | Date of earliest transaction, involving the vesting of restricted stock units and subsequent share dispositions for tax purposes. |
| 03/17/2026 | Date the Form 4 was signed by John S. Hess, Jr. under Power of Attorney. |
Keywords
United Therapeutics, UTHR, Martine Rothblatt, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Common Stock, Executive Compensation, Share Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.